Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment
C. Zhao, M. P. Mule, A. J. Martins, I. Pinal-Fernandez, R. N. Donahue, J. Chen, J. Schlom, J. L. Gulley, A. Mammen, J. S. Tsang, A. Rajan
The paper identifies pre-treatment immune signatures associated with immune-related adverse events (irAEs) in thymic cancer patients receiving checkpoint inhibitors using CITE-seq.
bioRxiv · Jun 5, 2022 · PreprintImmunology